[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRa8wOxVTs5lhznTd0q_6jAtCQcWMywyMwPGgqtd1Z3k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":73,"rows":80},"Maria Sklodowska-Curie National Research Institute of Oncology",[4],64,false,16,8,78960,9,43,[14,16,19,22,25,27,29,31],{"name":15,"count":11},"Colorectal Cancer",{"name":17,"count":18},"Rectal Cancer",6,{"name":20,"count":21},"Myxoid Liposarcoma",3,{"name":23,"count":24},"Prostate Cancer",2,{"name":26,"count":24},"Ventricular Tachycardia",{"name":28,"count":24},"Cervical Cancer",{"name":30,"count":24},"Cardiotoxicity",{"name":32,"count":24},"Screening",[34,39,44,48,53,58,63,68],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06128863","Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial","2025-04-30","Pembrolizumab, Eftilagimod alfa",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04875611","Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment","2025-12-31","Opdivo",{"nctId":45,"briefTitle":46,"date":42,"intervention":47},"NCT04920968","Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia\u002FPALG ALL7 \"OVERALL\"","Obinutuzumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05563467","Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.","2027-05-31","Pembrolizumab 25 MG\u002FML [Keytruda]",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04861207","Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes","2027-12-31","Cladribine",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05271162","Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines","2028-01-01","Empagliflozin 10 MG",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06472583","Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer","2028-02-28","Keytruda",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06449781","177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer","2030-11","Lutetium (177Lu) vipivotide tetraxetan",[74,75,76,77,78,79],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[81,105,135,156,178,196,222,243,263,284,310,336,375,400,418,436,460,486,511,552,581,599,617,635,653,679,706],{"intervention":62,"totalTrials":82,"cells":83},1,{"EARLY_PHASE1":84,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":101,"NA":103},{"trials":85,"activeCount":86},[],0,{"trials":88,"activeCount":86},[],{"trials":90,"activeCount":86},[],{"trials":92,"activeCount":82,"soonestReadout":61},[93],{"nctId":59,"briefTitle":60,"status":94,"phases":95,"primaryCompletion":61,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":100},"RECRUITING",[77],"2028-02-01","2023-09-30",220,[30],[62],{"trials":102,"activeCount":86},[],{"trials":104,"activeCount":86},[],{"intervention":72,"totalTrials":24,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":108,"activeCount":86},[],{"trials":110,"activeCount":86},[],{"trials":112,"activeCount":82,"soonestReadout":71},[113,119],{"nctId":69,"briefTitle":70,"status":94,"phases":114,"primaryCompletion":71,"completion":71,"start":115,"enrollment":116,"conditions":117,"interventions":118},[76],"2025-01-09",200,[23],[72],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":86,"conditions":126,"interventions":128},"NCT06199453","The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial","WITHDRAWN",[76],"2027-11","2024-01",[127],"Adenoid Cystic Carcinoma",[72],{"trials":130,"activeCount":86},[],{"trials":132,"activeCount":86},[],{"trials":134,"activeCount":86},[],{"intervention":43,"totalTrials":82,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":138,"activeCount":86},[],{"trials":140,"activeCount":86},[],{"trials":142,"activeCount":82,"soonestReadout":42},[143],{"nctId":40,"briefTitle":41,"status":94,"phases":144,"primaryCompletion":42,"completion":42,"start":145,"enrollment":146,"conditions":147,"interventions":149},[76],"2021-08-26",32,[148],"Nasopharyngeal Cancer",[43],{"trials":151,"activeCount":86},[],{"trials":153,"activeCount":86},[],{"trials":155,"activeCount":86},[],{"intervention":47,"totalTrials":82,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":159,"activeCount":86},[],{"trials":161,"activeCount":86},[],{"trials":163,"activeCount":82,"soonestReadout":42},[164],{"nctId":45,"briefTitle":46,"status":94,"phases":165,"primaryCompletion":42,"completion":42,"start":166,"enrollment":167,"conditions":168,"interventions":170},[76],"2021-10-05",124,[169],"CD20-positive Acute Lymphoblastic Leukemia",[47,171],"Rituximab",{"trials":173,"activeCount":86},[],{"trials":175,"activeCount":86},[],{"trials":177,"activeCount":86},[],{"intervention":171,"totalTrials":82,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":190,"PHASE4":192,"NA":194},{"trials":181,"activeCount":86},[],{"trials":183,"activeCount":86},[],{"trials":185,"activeCount":82,"soonestReadout":42},[186],{"nctId":45,"briefTitle":46,"status":94,"phases":187,"primaryCompletion":42,"completion":42,"start":166,"enrollment":167,"conditions":188,"interventions":189},[76],[169],[47,171],{"trials":191,"activeCount":86},[],{"trials":193,"activeCount":86},[],{"trials":195,"activeCount":86},[],{"intervention":38,"totalTrials":82,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":199,"activeCount":86},[],{"trials":201,"activeCount":86},[],{"trials":203,"activeCount":82,"soonestReadout":37},[204],{"nctId":35,"briefTitle":36,"status":205,"phases":206,"primaryCompletion":37,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":215},"ACTIVE_NOT_RECRUITING",[76],"2027-04-30","2023-07-17",40,[211,212,213,214],"Neoadjuvant","Immunotherapy","Sarcoma,Soft Tissue","Radiation Therapy",[38],{"trials":217,"activeCount":86},[],{"trials":219,"activeCount":86},[],{"trials":221,"activeCount":86},[],{"intervention":52,"totalTrials":82,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":225,"activeCount":86},[],{"trials":227,"activeCount":86},[],{"trials":229,"activeCount":82,"soonestReadout":51},[230],{"nctId":49,"briefTitle":50,"status":94,"phases":231,"primaryCompletion":51,"completion":51,"start":232,"enrollment":233,"conditions":234,"interventions":236},[76],"2023-01-31",24,[235],"Adrenocortical Carcinoma",[52],{"trials":238,"activeCount":86},[],{"trials":240,"activeCount":86},[],{"trials":242,"activeCount":86},[],{"intervention":57,"totalTrials":82,"cells":244},{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":257,"PHASE4":259,"NA":261},{"trials":246,"activeCount":86},[],{"trials":248,"activeCount":86},[],{"trials":250,"activeCount":82,"soonestReadout":56},[251],{"nctId":54,"briefTitle":55,"status":205,"phases":252,"primaryCompletion":56,"completion":56,"start":253,"enrollment":209,"conditions":254,"interventions":256},[76],"2021-10-07",[255],"Acute Myeloid Leukemia Myelodysplastic Syndromes",[57],{"trials":258,"activeCount":86},[],{"trials":260,"activeCount":86},[],{"trials":262,"activeCount":86},[],{"intervention":67,"totalTrials":82,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":278,"PHASE4":280,"NA":282},{"trials":266,"activeCount":86},[],{"trials":268,"activeCount":86},[],{"trials":270,"activeCount":82,"soonestReadout":66},[271],{"nctId":64,"briefTitle":65,"status":94,"phases":272,"primaryCompletion":66,"completion":66,"start":273,"enrollment":274,"conditions":275,"interventions":277},[76],"2024-04-11",78,[276],"Breast Cancer",[67],{"trials":279,"activeCount":86},[],{"trials":281,"activeCount":86},[],{"trials":283,"activeCount":86},[],{"intervention":285,"totalTrials":82,"cells":286},"Aspirin",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":308},{"trials":288,"activeCount":86},[],{"trials":290,"activeCount":86},[],{"trials":292,"activeCount":86},[],{"trials":294,"activeCount":86},[],{"trials":296,"activeCount":86},[297],{"nctId":298,"briefTitle":299,"status":300,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT01549418","The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin","UNKNOWN",[78],"2015-09","2012-09",760,[306],"Gastrointestinal Hemorrhage",[285],{"trials":309,"activeCount":86},[],{"intervention":311,"totalTrials":82,"cells":312},"Sucralfate",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":334},{"trials":314,"activeCount":86},[],{"trials":316,"activeCount":86},[],{"trials":318,"activeCount":86},[],{"trials":320,"activeCount":86},[],{"trials":322,"activeCount":86},[323],{"nctId":324,"briefTitle":325,"status":326,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT01613534","Combined Therapy in Radiation Proctopathy","COMPLETED",[78],"2007-06","2003-06",122,[332],"Chronic Radiation Proctitis",[311],{"trials":335,"activeCount":86},[],{"intervention":337,"totalTrials":24,"cells":338},"G-CSF",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":371,"NA":373},{"trials":340,"activeCount":86},[],{"trials":342,"activeCount":86},[],{"trials":344,"activeCount":86},[],{"trials":346,"activeCount":86},[347,359],{"nctId":348,"briefTitle":349,"status":326,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT01908621","Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.",[77],"2016-03-18","2017-10-27","2013-03-20",90,[356],"Multiple Myeloma",[337,358],"Cytosine arabinoside + G-CSF",{"nctId":360,"briefTitle":361,"status":300,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":354,"conditions":366,"interventions":369},"NCT02722733","Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma",[77],"2017-03","2017-04","2016-03",[367,368],"Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma",[337,370],"Cytosine arabinoside with G-CSF",{"trials":372,"activeCount":86},[],{"trials":374,"activeCount":86},[],{"intervention":376,"totalTrials":82,"cells":377},"Hormonal treatment",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":396,"NA":398},{"trials":379,"activeCount":86},[],{"trials":381,"activeCount":86},[],{"trials":383,"activeCount":86},[],{"trials":385,"activeCount":86},[386],{"nctId":387,"briefTitle":388,"status":300,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT01839994","Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer",[77],"2016-12","2018-12","2013-06",350,[23],[376],{"trials":397,"activeCount":86},[],{"trials":399,"activeCount":86},[],{"intervention":358,"totalTrials":82,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":414,"NA":416},{"trials":403,"activeCount":86},[],{"trials":405,"activeCount":86},[],{"trials":407,"activeCount":86},[],{"trials":409,"activeCount":86},[410],{"nctId":348,"briefTitle":349,"status":326,"phases":411,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":412,"interventions":413},[77],[356],[337,358],{"trials":415,"activeCount":86},[],{"trials":417,"activeCount":86},[],{"intervention":370,"totalTrials":82,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":432,"NA":434},{"trials":421,"activeCount":86},[],{"trials":423,"activeCount":86},[],{"trials":425,"activeCount":86},[],{"trials":427,"activeCount":86},[428],{"nctId":360,"briefTitle":361,"status":300,"phases":429,"primaryCompletion":363,"completion":364,"start":365,"enrollment":354,"conditions":430,"interventions":431},[77],[367,368],[337,370],{"trials":433,"activeCount":86},[],{"trials":435,"activeCount":86},[],{"intervention":437,"totalTrials":82,"cells":438},"Additional consolidation chemotherapy",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":440,"activeCount":86},[],{"trials":442,"activeCount":86},[],{"trials":444,"activeCount":86},[445],{"nctId":446,"briefTitle":447,"status":300,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"NCT05241574","Planned Non-operative Management for Rectal Cancer",[76],"2023-10","2021-08-03",23,[17],[437],{"trials":455,"activeCount":86},[],{"trials":457,"activeCount":86},[],{"trials":459,"activeCount":86},[],{"intervention":461,"totalTrials":82,"cells":462},"Axitinib",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":464,"activeCount":86},[],{"trials":466,"activeCount":86},[],{"trials":468,"activeCount":86},[469],{"nctId":470,"briefTitle":471,"status":326,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT04258956","A Study of Avelumab In Combination With Axitinib in Patients With Unresectable\u002FMetastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy",[76],"2021-04-30","2023-04-30","2019-04-30",58,[478],"Gastrointestinal Stromal Tumors",[461],{"trials":481,"activeCount":86},[],{"trials":483,"activeCount":86},[],{"trials":485,"activeCount":86},[],{"intervention":487,"totalTrials":82,"cells":488},"Liposomal Annamycin",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":505,"PHASE4":507,"NA":509},{"trials":490,"activeCount":86},[],{"trials":492,"activeCount":86},[],{"trials":494,"activeCount":86},[495],{"nctId":496,"briefTitle":497,"status":300,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":6,"conditions":501,"interventions":504},"NCT05518526","Phase 1b\u002F2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases",[75,76],"2025-08","2022-08-23",[502,503],"Soft Tissue Sarcoma","Pulmonary Metastasis",[487],{"trials":506,"activeCount":86},[],{"trials":508,"activeCount":86},[],{"trials":510,"activeCount":86},[],{"intervention":512,"totalTrials":82,"cells":513},"Sequential chemotherapy - 3 courses of AI",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":515,"activeCount":86},[],{"trials":517,"activeCount":86},[],{"trials":519,"activeCount":86},[520],{"nctId":521,"briefTitle":522,"status":300,"phases":523,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":545},"NCT03651375","Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall",[76],"2019-12-31","2022-03","2017-02-11",46,[529,530,531,532,533,534,535,536,537,538,20,539,540,541,542,543,544],"Sarcoma","Fibrosarcoma","Leiomyosarcoma","Liposarcoma","Myosarcoma","Histiocytic Sarcoma","Synovial Sarcoma","Lymphangiosarcoma","Malignant Peripheral Nerve Sheath Tumors","Myxofibrosarcoma","Undifferentiated Sarcoma","Pleomorphic Liposarcoma","Undifferentiated Pleomorphic Sarcoma","Dedifferentiated Liposarcoma","Pleomorphic Rhabdomyosarcoma","Malignant Triton Tumor",[512],{"trials":547,"activeCount":86},[],{"trials":549,"activeCount":86},[],{"trials":551,"activeCount":86},[],{"intervention":553,"totalTrials":82,"cells":554},"HLA-A1-binding MAGE-1\u002FMAGE-3 multipeptide-pulsed autologous dendritic cell vaccine",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":575,"PHASE4":577,"NA":579},{"trials":556,"activeCount":86},[],{"trials":558,"activeCount":86},[],{"trials":560,"activeCount":86},[561],{"nctId":562,"briefTitle":563,"status":300,"phases":564,"primaryCompletion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT01082198","Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes",[75,76],"2010-04","2002-10",22,[569],"Melanoma (Skin)",[553,571,572,573,574],"HLA-A2-binding TYR\u002FMART-1\u002Fgp100 multipeptide-pulsed autologous dendritic cell vaccine","autologous melanoma lysate-pulsed autologous dendritic cell vaccine","autologous melanoma lysate\u002FKLH-pulsed autologous dendritic cell vaccine","dendritic cell-idiotype-keyhole limpet hemocyanin vaccine",{"trials":576,"activeCount":86},[],{"trials":578,"activeCount":86},[],{"trials":580,"activeCount":86},[],{"intervention":571,"totalTrials":82,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":584,"activeCount":86},[],{"trials":586,"activeCount":86},[],{"trials":588,"activeCount":86},[589],{"nctId":562,"briefTitle":563,"status":300,"phases":590,"primaryCompletion":565,"start":566,"enrollment":567,"conditions":591,"interventions":592},[75,76],[569],[553,571,572,573,574],{"trials":594,"activeCount":86},[],{"trials":596,"activeCount":86},[],{"trials":598,"activeCount":86},[],{"intervention":572,"totalTrials":82,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":602,"activeCount":86},[],{"trials":604,"activeCount":86},[],{"trials":606,"activeCount":86},[607],{"nctId":562,"briefTitle":563,"status":300,"phases":608,"primaryCompletion":565,"start":566,"enrollment":567,"conditions":609,"interventions":610},[75,76],[569],[553,571,572,573,574],{"trials":612,"activeCount":86},[],{"trials":614,"activeCount":86},[],{"trials":616,"activeCount":86},[],{"intervention":573,"totalTrials":82,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":620,"activeCount":86},[],{"trials":622,"activeCount":86},[],{"trials":624,"activeCount":86},[625],{"nctId":562,"briefTitle":563,"status":300,"phases":626,"primaryCompletion":565,"start":566,"enrollment":567,"conditions":627,"interventions":628},[75,76],[569],[553,571,572,573,574],{"trials":630,"activeCount":86},[],{"trials":632,"activeCount":86},[],{"trials":634,"activeCount":86},[],{"intervention":574,"totalTrials":82,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":638,"activeCount":86},[],{"trials":640,"activeCount":86},[],{"trials":642,"activeCount":86},[643],{"nctId":562,"briefTitle":563,"status":300,"phases":644,"primaryCompletion":565,"start":566,"enrollment":567,"conditions":645,"interventions":646},[75,76],[569],[553,571,572,573,574],{"trials":648,"activeCount":86},[],{"trials":650,"activeCount":86},[],{"trials":652,"activeCount":86},[],{"intervention":654,"totalTrials":82,"cells":655},"CyberKnife",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":657,"activeCount":86},[],{"trials":659,"activeCount":86},[],{"trials":661,"activeCount":86},[662],{"nctId":663,"briefTitle":664,"status":300,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT02406105","An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease",[76],"2018-06","2020-12","2015-01",27,[671],"Parkinson Disease",[654],{"trials":674,"activeCount":86},[],{"trials":676,"activeCount":86},[],{"trials":678,"activeCount":86},[],{"intervention":680,"totalTrials":82,"cells":681},"Omeprazole 120 mg",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":683,"activeCount":86},[],{"trials":685,"activeCount":86},[],{"trials":687,"activeCount":86},[],{"trials":689,"activeCount":86},[],{"trials":691,"activeCount":86},[],{"trials":693,"activeCount":86},[694],{"nctId":695,"briefTitle":696,"status":326,"phases":697,"primaryCompletion":698,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},"NCT04154748","Argon Plasma Coagulation for Barrett's Esophagus",[79],"2015-02-10","2019-07-05","2002-06-04",71,[703],"Barretts Esophagus With Low Grade Dysplasia",[680,705],"Omeprazole 40 mg",{"intervention":705,"totalTrials":82,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":709,"activeCount":86},[],{"trials":711,"activeCount":86},[],{"trials":713,"activeCount":86},[],{"trials":715,"activeCount":86},[],{"trials":717,"activeCount":86},[],{"trials":719,"activeCount":86},[720],{"nctId":695,"briefTitle":696,"status":326,"phases":721,"primaryCompletion":698,"completion":699,"start":700,"enrollment":701,"conditions":722,"interventions":723},[79],[703],[680,705]]